Free Trial
→ Tesla. SolarCity. Twitter. This $4 stock is next. (From Behind the Markets) (Ad)tc pixel Free SVRA Stock Alerts

Savara (SVRA) News Today

Savara logo
$5.06 -0.03 (-0.59%)
Closing price 04:00 PM Eastern
Extended Trading
$5.16 +0.11 (+2.08%)
As of 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SVRA Latest News

Savara Announces Chief Financial and Administrative Officer Transition
June 8 at 4:05 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20260608876987/en/savara-announces-chief-financial-and-administrative-officer-transition/
Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns
June 8 at 3:35 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/assessing-savara-svra-valuation-shares-171334905.html
Oppenheimer Sticks to Their Buy Rating for Savara (SVRA)
June 5 at 7:15 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SVRA-Q/pressreleases/2303559/oppenheimer-sticks-to-their-buy-rating-for-savara-svra/
Analysts Offer Insights on Healthcare Companies: Savara (SVRA) and Biogen (BIIB)
May 30, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SVRA-Q/pressreleases/2214987/analysts-offer-insights-on-healthcare-companies-savara-svra-and-biogen-biib/
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
May 27, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260527034505/en/savara-announces-participation-in-the-2026-jefferies-global-healthcare-conference/
Savara: The Rare Disease Funnel Is Becoming A Commercial Asset
May 27, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4909114-savara-stock-rare-disease-funnel-is-becoming-a-commercial-asset
Savara Inc. (SVRA) Reports Q1 Financial Results
May 22, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/savara-inc-svra-reports-q1-financial-results-1767480/
5 Best Penny Stocks to Buy for Long Term
May 21, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/5-best-penny-stocks-to-buy-for-long-term-1765440/
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
May 20, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260520792505/en/savara-presented-new-biomarker-data-from-the-impala-2-phase-3-clinical-trial-of-molgramostim-inhalation-solution-molgramostim-in-autoimmune-pulmonary-alveolar-proteinosis-apap-at-the-american-thoracic-society-ats-international-conference-2026/
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar ...
May 19, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/savara-announces-exercise-capacity-data-185500185.html
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
May 19, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260519029544/en/savara-presented-long-term-efficacy-and-safety-data-from-the-ongoing-impala-2-phase-3-clinical-trial-open-label-ol-extension-of-molgramostim-inhalation-solution-molgramostim-in-autoimmune-pulmonary-alveolar-proteinosis-apap/
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
May 18, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260518925976/en/savara-announces-new-exercise-capacity-data-from-the-impala-2-phase-3-clinical-trial-of-molgramostim-inhalation-solution-molgramostim-in-autoimmune-pulmonary-alveolar-proteinosis-apap/
Guggenheim Reaffirms Their Buy Rating on Savara (SVRA)
May 15, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SVRA-Q/pressreleases/1928793/guggenheim-reaffirms-their-buy-rating-on-savara-svra/
Savara (SVRA) Receives a Buy from Piper Sandler
May 15, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SVRA-Q/pressreleases/1929432/savara-svra-receives-a-buy-from-piper-sandler/
Savara Reports First Quarter Financial Results and Provides Business Update
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512677993/en/savara-reports-first-quarter-financial-results-and-provides-business-update/
Swedbank AB Has $5.13 Million Position in Savara Inc. $SVRA
May 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-swedbank-ab-has-513-million-position-in-savara-inc-svra-2026-05-10/
Nan Fung Trinity HK Ltd. Takes $10.18 Million Position in Savara Inc. $SVRA
May 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nan-fung-trinity-hk-ltd-takes-1018-million-position-in-savara-inc-svra-2026-05-10/
Savara Inc. $SVRA Position Boosted by F m Investments LLC
May 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-savara-inc-svra-position-boosted-by-f-m-investments-llc-2026-05-10/
Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim
April 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/assessing-savara-svra-valuation-fda-170321523.html
Analysts Offer Insights on Healthcare Companies: Savara (SVRA) and Rhythm Pharmaceuticals (RYTM)
April 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RYTM-Q/pressreleases/1365090/analysts-offer-insights-on-healthcare-companies-savara-svra-and-rhythm-pharmaceuticals-rytm/
Savara Announces New Employment Inducement Grant
April 17, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260417883325/en/savara-announces-new-employment-inducement-grant/
Savara gets FDA review extension for lead asset
April 16, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4575623-savara-gets-fda-review-extension-for-lead-asset
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application ...
April 15, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/savara-announces-u-food-drug-200500011.html
SVRA stock slips post-market after FDA delays decision on pulmonary therapy
April 15, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/svra-stock-slips-post-market-after-fda-delays-decision-on-pulmonary-therapy/ar-AA20Z9X5
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
April 15, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260415775650/en/savara-announces-the-u.s.-food-drug-administration-fda-has-extended-the-review-period-for-the-molgramostim-inhalation-solution-molgramostim-biologics-license-application-bla-in-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap/
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
April 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260414233320/en/savara-to-present-new-data-at-the-american-thoracic-society-ats-2026-international-conference/
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune ...
April 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/savara-announces-u-k-medicines-120500132.html
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
April 7, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260407024140/en/savara-announces-the-u.k.-medicines-and-healthcare-products-regulatory-agency-mhra-has-accepted-the-molbreevi*-marketing-authorisation-application-maa-for-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap/
Analysts Offer Insights on Healthcare Companies: Savara (SVRA) and Edwards Lifesciences (EW)
April 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SVRA/pressreleases/1071898/analysts-offer-insights-on-healthcare-companies-savara-svra-and-edwards-lifesciences-ew/
Guggenheim Keeps Their Buy Rating on Savara (SVRA)
April 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SVRA/pressreleases/1086379/guggenheim-keeps-their-buy-rating-on-savara-svra/
Savara Inc.
April 1, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/SVRA/company-profile
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune ...
March 30, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/savara-announces-european-medicines-agency-120500176.html
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
March 30, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260330927904/en/savara-announces-european-medicines-agency-ema-validation-of-marketing-authorization-application-maa-for-molbreevi*-in-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap/
Savara reports 2025 results, advances MOLBREEVI toward approval
March 23, 2026  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/savara-reports-2025-results-advances-molbreevi-toward-approval/ar-AA1ZddhP
Savara (SVRA) Gets a Buy from LifeSci Capital
March 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/887075/savara-svra-gets-a-buy-from-lifesci-capital/
VR Adviser Adds Over 1 Million Savara Shares
March 15, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/03/15/vr-adviser-adds-over-1-million-savara-shares/
Savara says FDA review of MOLBREEVI to proceed without advisory committee
March 15, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/savara-says-fda-review-of-molbreevi-to-proceed-without-advisory-committee/ar-AA1YEio8
Savara Signs Long-Term Lease for New Headquarters
March 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/savara-signs-long-term-lease-for-new-headquarters?utm_source=marketbeat.com&utm_medium=referral
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
March 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260313815938/en/savara-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-update/
Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVI - What's Changed
March 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/savara-svra-down-8-0-101217823.html
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
March 6, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260306043046/en/savara-provides-regulatory-update-on-the-molbreevi*-development-program-in-autoimmune-pulmonary-alveolar-proteinosis-autoimmune-pap/
Savara Announces Participation in 2026 Citizens Life Sciences Conference
March 4, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260304462858/en/savara-announces-participation-in-2026-citizens-life-sciences-conference/
Savara Inc. Common Stock (SVRA) Institutional Holdings
February 28, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/svra/institutional-holdings
Savara grants inducement equity awards to new employee
February 23, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/savara-grants-inducement-equity-awards-to-new-employee/ar-AA1WU1vC
SVRA stock rises after hours as FDA grants priority review for lung disorder therapy
February 20, 2026  |  msn.comhttps://www.msn.com/en-in/health/other/svra-stock-rises-after-hours-as-fda-grants-priority-review-for-lung-disorder-therapy/ar-AA1WLVnZ
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
February 20, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260220017435/en/Savara-Announces-the-U.S.-Food-and-Drug-Administration-FDA-Filed-the-MOLBREEVI*-Biologics-License-Application-BLA-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/
Savara Advances Pediatric aPAP Trial With Inhaled Molgramostim, Extending Its Rare Lung Disease Reach
February 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/savara-advances-pediatric-apap-trial-with-inhaled-molgramostim-extending-its-rare-lung-disease-reach?utm_source=marketbeat.com&utm_medium=referral
Savara Announces New Employment Inducement Grant
February 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260213924701/en/savara-announces-new-employment-inducement-grant/
Savara Insiders Added US$535.6k Of Stock To Their Holdings
February 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/savara-insiders-added-us-535-114223734.html
Savara secures path to $150M as FDA decision nears for rare lung drug
February 6, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/savara-secures-path-to-150m-as-fda-decision-nears-for-rare-lung-drug/ar-AA1VOePS
Get Savara News Delivered to You Automatically

Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SVRA Media Mentions By Week

SVRA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SVRA
News Sentiment
▼
0.52

0.50
▲
Average
Medical
News Sentiment

SVRA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SVRA Articles
This Week
▼
3

8
▲
SVRA Articles
Average Week

Get the Latest News and Ratings for SVRA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Savara and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools

Related Companies
Headlines Tools

This page (NASDAQ:SVRA) was last updated on 6/8/2026 by MarketBeat.com Staff.
From Our Partners
The chokepoint supplier behind SpaceX's $1.75 trillion empire
When Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...
Behind the Markets | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
$36 million a day says something big is coming
Institutional capital is flowing into one thesis at a rate of $36 million per day - $25,000 every single minut...
Porter & Company | Sponsoredtc pixel
One hidden supplier shipped 5 billion parts to SpaceX
Most investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...
Weiss Ratings | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Have you tried Elon Musk’s 70X AI agent?
Jeff Brown picked Nvidia in 2016 - it's up 25,155% since. He recommended Bitcoin at $240 - it's up 31,219% sin...
Brownstone Research | Sponsoredtc pixel
June 12th. After That, This Is Gone.
A small publicly traded company holds $9 billion in private SpaceX shares from a 2023 Starlink deal - and it's...
StocksToTrade | Sponsoredtc pixel